Skip to Primary Content
Skip to Footer
About
About Mannkind
Our Values
Executive Leadership
Board of Directors
History of Innovation
Products & Pipeline
Products & Pipeline
Pipeline Chart
Clinical Trials
About Clinical Trials
MannKind Trials
Scientific Advisory Board
Publications
Medical Affairs
Partners
Partnering with Mannkind
Technosphere
Innholation innovation
BluHale Inhalation
H-Patch
Intelectual property
Careers
Mannkind Careers
Locations
Department
Open Positions
Benefits
Internships & Fellowships
Newsroom
Investors
Investing in Mannkind
Events & Presentations
Corporate Deck & Fact Sheet
Press Releases
SEC Filings
Financial Information
Annual Reports
Quarterly Results
ESG
Stock Information
Historic Price Lookup
Investment Calculator
Ownership Profile
Analyst Coverage
About
Our Values
Executive Leadership
Board of Directors
History of Innovation
Products & Pipeline
Pipeline Chart
Clinical Trials
About Clinical Trials
MannKind Trials
Scientific Advisory Board
Publications
Medical Affairs
Partners
Technosphere
Inhalation innovation
BluHale Inhalation
H-Patch
Intellectual property
Careers
Locations
Departments
Open Positions
Benefits
Internships & Fellowships
Newsroom
Investors
Events & Presentations
Corporate Deck
Press Releases
SEC Filings
Financial Information
Annual Reports
Quarterly Results
Corporate Governance
ESG
Stock Information
Historic Price Lookup
Investment Calculator
Ownership Profile
Analyst Coverage
News & Events
June 23, 2026
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes
previous post
next post
FDA Approval:
New Option in Pediatric Diabetes Care
learn more
about Afrezza news
×
